For instance, in non-small cell lung cancer (NSCLC), patients receiving EGFR inhibitors like osimertinib often relapse due to the emergence of EGFR C797S resistance mutations [3,4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.